Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Nanocovax COVID-19 Vaccine
NCT04683484Phase 2Unknown
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nanocovax in coronavirus disease 2019 (COVID-19), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Status: unknown.
02
Drugs
nanocovax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04683484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683484.